EXACT Sciences Corporation

EXACT Sciences — Conference Presentation (January 2018)

31 slides from EXACT Sciences's conference presentation, Jan 8, 2018

  1. Slide 1: Forward-looking statements

    This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statem

  2. Slide 2: Our Vision

    Our Vision Exact Sciences is committed to helping win the war on cancer through early detection. 3

  3. Slide 3: Pathway to success in 2018 and future

    4 Pathway to success in 2018 and future

  4. Slide 4: Colon cancer: America's second deadliest cancer

    Source: American Cancer Society, Cancer Facts & Figures 2018; all figures annual Colon cancer: America’s second deadliest cancer Source: American Cancer Society, Cancer Facts & Figures 2017; all figures annual new diagnoses 140,250 deaths 50,630 Annual Cancer Deaths 5 15,850 29,430 41,400 44,330 50,

  5. Slide 5: The most preventable, yet least prevented form of cancer

    Sources: J Natl Cancer Inst. 2009; 101:1225-1227 (Itzkowitz) Gastro 1997;112:594-692 (Winawer) 6 “The most preventable, yet least prevented form of cancer” – Journal of the National Cancer Institute 10+ years Pre-cancerous polyp Cancer

  6. Slide 6: America's stagnant colon cancer screening rate

    7 Sources: CDC NHIS survey results as published in the CDC’s MMWR between 2006 and 2017 America’s stagnant colon cancer screening rate Actual colon cancer screening rates 2005 2008 2010 2013 2015 2018 50% 52% 59% 58% 62% 80% goal

  7. Slide 7: Cologuard: Addressing the colon cancer challenge

    8 Source: Imperiale TF et al., N Engl J Med (2014) *For stage I and II cancers; 87% specificity Cologuard: Addressing the colon cancer challenge 94% early stage cancer sensitivity* developed with Easy to use Non-invasive No preparation No sedation No time off work

  8. Slide 8: Cologuard is changing lives every day

    9 Cologuard is changing lives every day “My positive Cologuard test last year led to a colonoscopy that revealed stage I cancer. I’m grateful to now be active and healthy as I travel the country with my husband.” - Brenda Savannah, GA

  9. Slide 9: Impact of Cologuard since launch

    *Estimates based on DeeP-C pivotal trial findings: Imperiale TF et al., N Engl J Med (2014) 10 Impact of Cologuard since launch People screened 923,000 ~4,300 Early-stage cancers detected *

  10. Slide 10: Strong Cologuard revenue growth

    11 Strong Cologuard revenue growth 2015 2016 Quarterly Cologuard revenue ($ Millions) 2017 * *Midpoint of preliminary, unaudited fourth quarter revenue range $1.5 $4.3 $8.1 $12.6 $14.4 $14.8 $21.2 $28.1 $35.2 $48.4 $57.6 $72.6 $87.4

  11. Slide 11: Cologuard demand continues to fuel volume growth

    12 Cologuard demand continues to fuel volume growth 2015 2016 Quarterly Cologuard tests completed 2017 4,000 11,000 21,000 34,000 38,000 40,000 54,000 68,000 82,000 100,000 135,000 161,000 176,000

  12. Slide 12: Increasing America's screening population

    Exact Sciences Laboratories data, Patient Satisfaction Survey, May-Dec 2017; n = 3,772 13 Increasing America’s screening population Screening history of Cologuard users 39% screened with colonoscopy 13% screened only with FIT/FOBT 48% never screened before

  13. Slide 13: Cologuard's growing provider penetration

    14 Cologuard’s growing provider penetration Total ordering providers 84K Primary Care Providers 4Q15 4Q17 4Q16 4Q14 6.5K Gastroenterologists 2.8K OBGYN’s 8.7K Other providers

  14. Slide 14: Exact Sciences' unique dataset addresses critical needs

    15 Exact Sciences’ unique dataset addresses critical needs Improve quality measures and outcomes Payers Improve quality measures and reporting capabilities Providers Increase compliance and repeat screening Patients

  15. Slide 15: A multi-billion dollar U.S. market opportunity

    16 A multi-billion dollar U.S. market opportunity *85 million average-risk, asymptomatic people ages 50-85, **Assumes revenue per test of $500-525 and 3-year interval for Cologuard, ***(176,000 completed tests * 4 to annualize * 3 to account for interval) / 85M 85M+ 2.5% Potential U.S. screening mar

  16. Slide 16: Clinical value of Cologuard: numbers needed to screen/treat

    17 Clinical value of Cologuard: comparing numbers needed to screen/treat 166 to find 1 colorectal cancer* 217 to prevent 1 heart attack*** Statins *Imperiale TF et al., N Engl J Med (2014) **Hendrick R et al., AJR (2012) – for ages 40-49 ***Chou R, Dana T, Blazina I, Daeges M, Jeanne TL., JAMA (2016

  17. Slide 17: Building infrastructure for long-term growth

    18 Building infrastructure for long-term growth Lab Operations Sales Teams Customer Care & Billing Medical Affairs Clinical & Regulatory Health Systems

  18. Slide 18: Investing in Exact Sciences' nationwide sales force

    19 Investing in Exact Sciences’ nationwide sales force Primary care sales force Educate physicians & office staff and improve repeat ordering of Cologuard Extend reach of sales force coverage and new physician outreach and pull through Inside sales force ~250 ~100 350 200 2017 2018 (est.)

  19. Slide 19: Driving patient compliance with colon cancer screening

    20 Cologuard’s compliance rate is derived from the number of completed tests reported divided by the number of collection kits shipped to patients during the 12-month period ending 60 days prior to Dec. 31, 2017, excluding program orders Driving patient compliance with colon cancer screening 65% Pat

  20. Slide 20: Strong customer satisfaction with Cologuard

    21 Sources: ZS survey conducted for Exact Sciences Aug-Sep 2017, n=211 Exact Sciences Laboratories patient satisfaction survey Jan-Dec 2017, n = 5,699 Strong customer satisfaction with Cologuard Providers’ expectations met or exceeded Patients rated Cologuard experience very positive 88% 98%

  21. Slide 21: Broad marketing strategy increasing Cologuard awareness

    22 Broad marketing strategy increasing Cologuard awareness National TV campaign Social & digital media National partnerships Feb 28 – Mar 4 National celebrity spokesperson TBA

  22. Slide 22: Investing in facilities and additional capacity

    23 Investing in facilities and additional capacity ~2M Expected annual capacity by mid-2019 >2.5M Expected annual capacity by mid-2018 145 Badger Road 1 Exact Lane Expected total capacity of more than 4.5 million tests by mid-2019

  23. Slide 23: Investing in future of Cologuard and pipeline

    24 Investing in future of Cologuard and pipeline Acquired rights to methylation marker used in Cologuard Acquired to augment and strengthen IT capabilities Acquired portfolio of protein biomarkers to complement pipeline

  24. Slide 24: Cancer is the 2nd leading cause of death globally

    Source: World Health Organization and Centers for Disease Control and Prevention 25 Cancer is the 2nd leading cause of death globally Expected 70% increase in new cancer cases globally within 20 years 1.7M new cancer cases 600k deaths 14M new cancer cases 8.8M deaths

  25. Slide 25: Cologuard success helping to reimagine cancer diagnostics

    26 Cologuard success helping to reimagine cancer diagnostics Exact Sciences has pieces in place to be successful in liquid biopsy PEOPLE PLATFORM MARKET Collaboration with Mayo Clinic Exact Sciences’ proven experience Multi-marker approach, proprietary technology, & platform Time, cost, & accuracy a

  26. Slide 26: Unique collaboration between Exact Sciences and Mayo Clinic

    27 Unique collaboration between Exact Sciences and Mayo Clinic

  27. Slide 27: Advantages of Exact Sciences' approach

    28 *Liquid biopsy study results only Advantages of Exact Sciences’ approach Highly sensitive and specific 3 study results with 90%+ sensitivity and specificity* Low cost Tens of dollars in reagents instead of hundreds Quick turn around time Hours instead of days Universal platform Leveraging Cologua

  28. Slide 28: Liquid biopsy a growth area for cancer diagnostics

    Source: Analyst estimates 29 Liquid biopsy a growth area for cancer diagnostics Exact Sciences focusing on early detection & recurrence Projected liquid biopsy market >$13B $200M Screening Minimum residual disease Recurrence monitoring Response monitoring Targeted therapy selection Clinical applicat

  29. Slide 29: Preliminary fourth-quarter and full-year 2017 results

    30 Preliminary fourth-quarter and full-year 2017 results Q4 2017 Revenue (millions) $86.9 - $87.9 $265.5 - $266.5 Y/Y growth % 148% 168% Completed Tests 176,000 571,000 Y/Y growth % 115% 134% FY 2017 Unaudited financial results

  30. Slide 30: Preliminary fourth-quarter and full-year 2017 results

    Preliminary fourth-quarter and full-year 2017 results Unaudited financial results Q4 2017 FY 2017 Revenue (millions) $86.9 - $87.9 $265.5 - $266.5 YIY growth % 148% 168% Completed Tests 176,000 571,000 YY growth % 115% 134%

  31. Slide 31: Slide 31

Exact Sciences — Conference Presentation (January 2018) on 6ix